Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
|
|
Ambrx Biopharma Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/12/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/12/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/12/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/12/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
SC 13G
| HOPU Reunion Co Ltd reports a 8.9% stake in Ambrx Biopharma Inc. |
| 10/06/2023 |
8-K
| Resignation/termination of a director |
| 08/25/2023 |
8-K
| Other Events Interactive Data |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/07/2023 |
4
| O'Connor Daniel J. (President and CEO) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 1,216,500 options to buy
@ $0 |
|
| 07/07/2023 |
4
| Nelson Sonja (CFO) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 389,000 options to buy
@ $0 |
|
| 07/07/2023 |
4
| Aromando Andrew (COO) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 389,000 options to buy
@ $0 |
|
| 06/28/2023 |
4
| Darwin Global Management, Ltd. (10% Owner) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Bought 5,384,063 options to buy
@ $0 |
|
| 06/28/2023 |
SC 13D/A
| Darwin Global Management, Ltd. reports a 27.5% stake in Ambrx Biopharma Inc. |
| 06/28/2023 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/09/2023 |
4
| Glover Stephen C. (Director) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 85,000 shares
@ $0
Granted 40,000 options to buy
@ $0
Granted 17,500 options to buy
@ $0 |
|
| 06/09/2023 |
4
| Chang Xiaowei (Director) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 85,000 options to buy
@ $0
Granted 125,000 options to buy
@ $0 |
|
| 06/09/2023 |
4
| Loesberg Janet (Director) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 85,000 shares
@ $0 |
|
| 06/09/2023 |
4
| MAIER PAUL V (Director) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 85,000 shares
@ $0 |
|
| 06/09/2023 |
4
| Hermans Kate (Director) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 85,000 shares
@ $0 |
|
| 06/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/26/2023 |
4
| Glover Stephen C. (Director) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 210,000 options to buy
@ $0 |
|
| 05/25/2023 |
SC 13D/A
| Darwin Global Management, Ltd. reports a 20.5% stake in Ambrx Biopharma Inc. |
| 05/25/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/19/2023 |
3
| Glover Stephen C. (Director) has filed a Form 3 on Ambrx Biopharma Inc. |
| 05/18/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/18/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
4
| Aromando Andrew (COO) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Granted 2,600,000 options to buy
@ $0 |
|
|
|
|